Fresh Tracks stops drug pipeline to save mon­ey as it keeps look­ing for an ex­it

Fresh Tracks Ther­a­peu­tics has hit pause on its drug de­vel­op­ment pipeline to save cap­i­tal re­sources and fig­ure out its ex­it strat­e­gy.

The re­search in­ter­rup­tion in­cludes fore­go­ing part two of a Phase I tri­al in­ves­ti­gat­ing its lead as­set FRTX-02 in atopic der­mati­tis. The pause will al­low the Boul­der, CO biotech to plan what’s next for the as­set based on pos­i­tive re­sults re­leased in March from the tri­al’s part-one por­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER